Intraperitoneal free cancer cells in gastric cancer: Pathology of peritoneal carcinomatosis and rationale for intraperitoneal chemotherapy/hyperthermic intraperitoneal chemotherapy in gastric cancer

25Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

Peritoneal carcinomatosis (PC) is one of the most common causes of death in gastric cancer patients. Intraperitoneal free cancer cells (IFCCs) play a very important role in forming PC, but the administration of intraperitoneal chemotherapy (IPC) and/or hyperthermic intraperitoneal chemotherapy (HIPEC) could be an effective treatment for IFCCs. This review focuses on the origin of IFCCs, the mechanism of PC formatting, the rationale of IPC/HIPEC, and the current clinical trials on IPC/HIPEC to treat advanced gastric cancer patients.

Cite

CITATION STYLE

APA

Ji, Z. H., Peng, K. W., & Li, Y. (2016). Intraperitoneal free cancer cells in gastric cancer: Pathology of peritoneal carcinomatosis and rationale for intraperitoneal chemotherapy/hyperthermic intraperitoneal chemotherapy in gastric cancer. Translational Gastroenterology and Hepatology. AME Publishing Company. https://doi.org/10.21037/tgh.2016.08.03

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free